ArticleInternational journal of cancer2026
Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The clinical features, treatment efficacy, and prognostic differences in melanoma patients with cavity carcinomatosis, which is of rare occurrence, are still unclear. A retrospective analysis was conducted on melanoma patients with cavity carcinomatosis treated at Fujian Cancer Hospital from 2007 to 2023, with follow-up ending in March 2024. The results showed that among 1430 melanoma patients, 79 had cavity carcinomatosis (5.5%). Median time to cavity carcinomatosis was 6.53 months (interquartile range: 0.23-26.20). The survival after melanoma cavity carcinomatosis was 5.23 months (95% CI: 4.39-6.07). Post-cavity carcinomatosis survival improved to 6.30 months with treatment, versus 1.13 months without (p = .001). Anti-BRAF treatment did not outperform with only 4.83 months of progression-free survival, and the objective response rate was 14.29%. The curative effect of chemotherapy and immunotherapy on BRAF wild-type patients was similar. LDH levels strongly correlated with cavity carcinomatosis survival; patients with LDH ≤ ULN and ULN < LDH ≤ 2.5ULN lived longer than those with LDH > 2.5ULN (6.77 vs. 5.13 vs. 2.67 months, p = .008). This indicated that melanoma with cavity carcinomatosis should be considered a distinct subtype that signifies a high mortality rate. Continuous anti-tumor therapy can still improve survival despite the lack of standout treatments after onset. Serum LDH levels hold the potential to serve as a crucial survival predictor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.